CNBX Pharmaceuticals (CNBX) News Today $0.01 0.00 (-19.57%) As of 03:53 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period CNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comCNBX Pharmaceuticals Inc CNBXNovember 5, 2023 | morningstar.comCNBX Historical DataOctober 10, 2023 | investing.comCNBX - CNBX Pharmaceuticals Inc.July 28, 2023 | finance.yahoo.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | benzinga.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaNovember 8, 2022 | finance.yahoo.comCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer TherapyOctober 18, 2022 | finance.yahoo.comCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and IsraelOctober 13, 2022 | finance.yahoo.comCNBX Pharmaceuticals Announces New Patent Granted in AustraliaSeptember 28, 2022 | finance.yahoo.comCNBX Pharmaceuticals IncSeptember 12, 2022 | reuters.comCNBX Pharmaceuticals Inc. (CNBX)August 16, 2022 | ca.finance.yahoo.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 10, 2022 | benzinga.comCNBX Pharmaceuticals Inc. (CNBXD)June 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc.May 14, 2022 | barrons.comCNBX pharma granted patent in Hong Kong for cancer therapyMay 5, 2022 | seekingalpha.comCNBX Pharmaceuticals Granted Patent in Hong KongMay 5, 2022 | finance.yahoo.comNovartis to save at least $1 billion by 2024 thanks to simplified structureApril 4, 2022 | msn.comVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killerApril 4, 2022 | msn.comWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stakeApril 4, 2022 | cnbc.comStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreApril 4, 2022 | msn.comCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit TodayApril 1, 2022 | cnbc.comWhat to watch today: Wall Street set to wrap up strong month but weak quarterApril 1, 2022 | cnbc.comStocks making the biggest moves premarket: Walgreens, Baidu, Novavax and othersApril 1, 2022 | msn.comVertex Pharmaceuticals reports positive data on non-opioid pain medicineApril 1, 2022 | msn.comCannabics Pharmaceuticals Changes Name to CNBX PharmaceuticalsMarch 28, 2022 | finance.yahoo.comAvicanna To Bring Its Cannabinoid-Based Drugs To Argentina Via 'Established' Pharma PartnerNovember 30, 2021 | benzinga.comCNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical TrialsNovember 4, 2021 | finance.yahoo.comMeet CNBX at Radiation Therapy Conference (RTC) 2021 in ChicagoOctober 26, 2021 | finance.yahoo.comRadiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of AdvisorsOctober 25, 2021 | finance.yahoo.comEDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBXOctober 21, 2021 | prnewswire.comCEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021October 19, 2021 | finance.yahoo.comCannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating CancerOctober 18, 2021 | finance.yahoo.comCEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference | MorningstarOctober 14, 2021 | morningstar.comCEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital ConferenceOctober 14, 2021 | finance.yahoo.comCannabics Announces New Corporate Logo, New Website and New Company PresentationSeptember 30, 2021 | finance.yahoo.comGabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in BostonSeptember 22, 2021 | finance.yahoo.comCannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health DiseasesSeptember 21, 2021 | finance.yahoo.comNeuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired MedicineSeptember 13, 2021 | finance.yahoo.comHemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of AdvisorsAugust 23, 2021 | finance.yahoo.comJ&J's Janssen Denied Data Protection Rights For Ketamine Analog Spravato In Canada, Court Rules 'Not An Innovative Drug'August 10, 2021 | benzinga.comWorld-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of AdvisorsAugust 4, 2021 | finance.yahoo.comClever Leaves And Biopharma Research Co. Will Study DNA Sequencing Of Cannabis Under 'Project Change Lives' InitiativeJuly 28, 2021 | benzinga.comNew Cannabis Products: A Professional Cosmetic Line, A CBD Sports Recovery Line And Marine CollageJuly 23, 2021 | benzinga.comWill Psychedelics Continue To Grow In 2021? Fund Managers Share Insights And Strategies As More Companies Go PublicJuly 23, 2021 | benzinga.com Get CNBX Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNBX Media Mentions By Week CNBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNBX News Sentiment▼0.000.74▲Average Medical News Sentiment CNBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNBX Articles This Week▼00▲CNBX Articles Average Week Get CNBX Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AQSP News AMMJ News ACAN News CBDS News FUTL News MCOA News MJNA News BUDZ News ZDPY News ZZLL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CNBX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNBX Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
